NCT04187547View on ClinicalTrials.gov

A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension

PHASE3WithdrawnINTERVENTIONAL

Timeline

Start Date

June 30, 2022

Primary Completion Date

December 31, 2023

Study Completion Date

February 28, 2024

Conditions

Alzheimer's Disease

Interventions

DRUG

Tricaprilin

"Powder formulation will be mixed with 240 mL water and shaken until fully dispersed.~Each dosing unit of AC-SD-03 contains 20 g of the active ingredients (tricaprilin)"

DRUG

Placebo

Matching placebo to AC-SD-03 will be mixed with 240 mL water and shaken until fully dispersed.